{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
First approved in 2019
Class:
STRUCTURALLY DIVERSE
Status:
First approved in 2007
Source:
BLA125158
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:raxorulimogene belzovacirepvec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:mesmulogene ancovacivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
INN:tipapkinogene sovacivec [INN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03294083: Phase 1/Phase 2 Interventional Recruiting Renal Cell Carcinoma
(2018)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02759588: Phase 1/Phase 2 Interventional Active, not recruiting Ovarian Cancer
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT04134312: Phase 1 Interventional Active, not recruiting Solid Metastatic Tumor
(2020)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00397345: Phase 3 Interventional Completed Clear Cell Renal Carcinoma
(2006)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01602562: Phase 3 Interventional Completed Herpes Simplex
(2012)
Source URL:
Class:
STRUCTURALLY DIVERSE